Study S000934

Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07325500
Acronym: REINFORCE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 30
Start: 2026-02-12
Primary completion: 2028-05-31
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Weight Gain
Interventions: DRUG:Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly; DRUG:Dose escalation to 2 mg semaglutide weekly then no semaglutide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:1R01DK142171-01A1

Registered primary outcomes

Percent weight regain from weeks 12-60 (microdosing period) [from week 12 to week 60]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.